Logo for Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals Investor Relations Material

Latest events

Logo for Satsuma Pharmaceuticals

Q1 2023

18 May, 2023
Logo for Satsuma Pharmaceuticals

Q4 2022

16 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Satsuma Pharmaceuticals Inc

Access all reports
Satsuma Pharmaceuticals Inc is a development-stage biopharmaceutical company focused on innovating therapeutic products for people suffering from migraine and other debilitating conditions. Its primary product candidate is STS101, a dihydroergotamine (DHE) nasal powder, aimed at offering a significant and differentiated treatment option for acute migraine attacks. Satsuma Pharmaceuticals is headquartered in South San Francisco, California, and its shares are listed on the Nasdaq.